<span>FGF21/sTGBFR2 gene therapy improves insulin resistance and hyperlipidemia in preclinical models of obesity and lipodystrophy, but effectiveness in these models are dependent on environmental temperature.</span>. Here, FGF21 is linked to lipodystrophy.